McMinn Rachel
- SEC CIK
- 0001606302
In the past year, 1 open-market sale filing worth $74.0K and no purchases.
Current role at each company
- NGNE Neurogene Inc.Chief Executive Officeras of Mar 30, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $74.0K
- 1 filing
- Net
- −$74.0K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists McMinn Rachel as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | McMinn RachelChief Executive Officer | SSale | −3.35K | $22.07 | −$74.0K | −0.2%1.34M after | 10b5-1 |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | McMinn RachelChief Executive Officer | PPurchase | +47.5K | $20.40 | +$969.0K | +3.8%1.30M after |